Navigation Links
Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
Date:6/17/2008

KENILWORTH, N.J., June 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) is scheduled to announce its sales and earnings results for the 2008 second quarter on Monday, July 21, 2008.

At 8 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2008 second quarter. Fred Hassan, Schering-Plough's chairman and CEO, and other members of management will host the conference call.

To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #50992673. A replay of the call will be available beginning later on July 21 through 5 p.m. on July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #50992673. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 20.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
2. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
3. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
4. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
5. Schering-Plough CEO Buys $2 Million in Common Shares
6. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
7. Schering-Plough Reports Financial Results for First Quarter of 2008
8. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
9. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
10. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
11. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 LayerBio is an MIT ... wound care. The National Eye Institute (NEI) at the ... Phase I SBIR grant to develop a drug-eluting intraocular ... most common cause of vision loss in people over ... According to Dr. Ken Mandell, LayerBio’s Founder and CEO, ...
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... March 7 On Thursday, March 13, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... call to discuss the company,s 2007 fourth,quarter achievements ... Numbers Thursday, March 13 8:30 a.m. ...
... team of researchers from the departments of macromolecular science ... of Engineering and the Louis Stokes Cleveland Department of ... a new type of polymer that displays chemoresponsive mechanic ... to soft plastic and vice versa in seconds when ...
... March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... to the,Company,s Board of Directors., "As the ... of the former Bayer Diagnostics and Diagnostic Products,Corporation, ... our Board," said Dr.,Paul Walker, President and CEO ...
Cached Biology Technology:Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 2Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 3Spectral appoints Anthony Bihl to Board of Directors 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... (GIVI) have identified a previously unknown function of APOBEC3G (A3G), ... lead to new approaches for controlling HIV infection. , ... of the National Academy of Sciences, USA. , The research, ... C. Greene, MD, PhD, explains why CD4 T cells ?the ...
... or stroke, paramedics, doctors, and nurses follow standardized protocols for ... odds for a full recovery. That's not the case if ... be fatal within a few hours and is often not ... new, multicenter research consortium, called Protocolized Care for Early Septic ...
... individual's immune system controls HIV during the earliest phases ... versions of key immune-system molecules called HLA Class I ... fragments of viral protein those molecules display to the ... a report in the November issue of PLOS Medicine, ...
Cached Biology News:Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
... of monoclonal antibody reactive against the complex IV ... highest in growing cultured cells. SURF1 is an ... is thought to participate in the folding of ... subunit. Mutations of SURF1, particularly ones that result ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: